Related Experiment Videos
Pulsed low dose rate brachytherapy for pelvic malignancies
P S Swift1, P Purser, L W Roberts
1Department of Radiation Oncology, University of California, San Francisco 94143, USA.
Summary
Pulsed low dose rate brachytherapy for pelvic malignancies offers excellent local control with no significant increase in acute toxicity compared to standard methods. Further trials are needed to assess late toxicity and optimize treatment parameters.
Area of Science:
- Oncology
- Radiation Oncology
- Medical Physics
Background:
- High dose rate (HDR) brachytherapy offers radiation safety and isodose optimization.
- Continuous low dose rate (CLDR) brachytherapy provides radiobiologic advantages.
- Pulsed low dose rate (PLDR) remote afterloading aims to combine benefits of HDR and CLDR brachytherapy.
Purpose of the Study:
- To evaluate acute toxicity and local control in patients with pelvic malignancies treated with PLDR brachytherapy.
- To compare PLDR brachytherapy outcomes with existing brachytherapy techniques.
Main Methods:
- Prospective clinical trial involving 65 patients with pelvic malignancies.
- 77 brachytherapy procedures using a PLDR Selectron unit with an Ir192 source.
- Prescribed doses of 0.40-0.85 Gy per pulse.
- Follow-up to assess Grade 3-5 acute and delayed toxicity, local control, and survival.
Main Results:
- Median follow-up of 16.1 months.
- Local control achieved in 48 cases.
- Grade 3-5 acute toxicity occurred in 6.5% of procedures.
- Actuarial incidence of delayed complications was 15% at 2 years.
- For cervix cancer patients, acute toxicity was 5.8% and delayed complications 14% at 2 years.
Conclusions:
- PLDR brachytherapy shows no significant increase in acute toxicity compared to standard CLDR.
- Excellent local control observed in initially treated patients.
- Longer follow-up is necessary for full assessment of local control and late toxicity.
- Further trials needed to determine optimal doses per pulse and treatment times.